drugset
drugset / Trial / NCT01291004

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

NCT01291004 ↗

Phase 1 Completed 206 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupOpen-labelBasic science

Summary

This study is being conducted to evaluate the impact of a 28-day oral contraceptive compared to two 28-day oral contraceptive regimens containing different synthetic progestins on ovarian follicular activity and hormone levels in healthy women.

Timeline

Start
2011-01-31
Primary completion
2012-03-31
Completion
2012-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Desogestrel Small molecule 0.15 mg Oral
Comparator Levonorgestrel Small molecule 0.1 mg Oral
Comparator drospirenone Unknown 0.3 mg Oral
Subject ethinyl estradiol Small molecule 0.01 mg Oral
Subject ethinyl estradiol Small molecule 0.02 mg Oral

Indications

No indication recorded.